Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Innovent and HutchMed Report Positive Results from Combo CRC Therapy

publication date: Jun 9, 2021

Suzhou Innovent Bio and HutchMed announced positive data from their combination therapy for colorectal cancer. The regimen combines Innovent's approved PD-1, Tyvyt® (sintilimab injection) with HutchMed's VEGFR inhibitor, Elunate® (fruquintinib), as a third-line therapy for CRC. In 44 previously treated CRC patients, the objective response rate was 22.7%, about double the ORR of Elunate alone. The Phase Ib trial tested safety and efficacy of the combination and determined the recommended Phase II dose. More details...

Stock Symbols: (HK: 01801) (NSDQ/AIM: HCM)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital